<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511810</url>
  </required_header>
  <id_info>
    <org_study_id>McNamara Omega3 MDD</org_study_id>
    <nct_id>NCT00511810</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder</brief_title>
  <official_title>Evaluation of Omega-3 Fatty Acids as a Treatment-adjunct in Adolescent Patients With Major Depressive Disorder Exhibiting Partial Response to SSRI Medications: An Open-label Neuroimaging Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Inflammation Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to determine the effects of 10-week adjunctive
      supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity
      and biochemistry in adolescents with MDD.

      The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently
      increase prefrontal cortical functional activation during sustained attention and increase
      regional biochemical indices of cortical metabolism and integrity concentrations in
      association with reductions in depressive symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 10-week open-label EPA+DHA treatment trial in adolescent (aged 12-18 years)
      patients with major depressive disorder exhibiting partial response to SSRI medications.
      After a screening visit, patients were randomized (stratified by gender) to open-label fish
      oil supplements at a fixed dose of either 2.4 g/day or 15 g/day (2 tablespoons/day) for 10
      weeks.

      A physical examination, a complete blood count (CBC), and thyroid stimulating hormone (TSH)
      levels were determined at baseline and Week 10, and vital signs (pulse, blood pressure,
      weight, height, body mass index, temperature) were obtained at each visit. At each visit,
      safety and tolerability were assessed using a structured side effect interview, the Side
      Effects Form for Children and Adolescents.

      At baseline and all weekly visits, depression symptom severity was determined with the
      Children's Depression Rating Scale-Revised (CDRS-R), a 17-item observer-rated questionnaire,
      and remission was defined as a CDRS-R score of ≥28. If a patient's depressive symptoms
      worsened over the course of the trial (defined as 30% worsening relative to baseline on two
      consecutive visits using CDRS-R scores), they were withdrawn from the study. In view of the
      potential risk for developing hypomanic symptoms following LCn-3 fatty acid supplementation,
      manic symptom severity was monitored over the course of the trial with the Young Mania Rating
      Scale (YMRS), an 11-item observer-rated questionnaire.

      fMRI scans were performed at baseline and at 10 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood Symptoms Ratings</measure>
    <time_frame>10 weeks</time_frame>
    <description>Depression symptom severity was determined with the Children's Depression Rating Scale-Revised (CDRS-R), which is a brief rating scale based on a semi-structured interview with the child. It is a 17-item observer-rated questionnaire where the 17 symptom areas are rated on a 6- or 7-point scale. Total score ranges from a low (not depressed) of 17 to a maximum (very depressed) of 108. Remission was defined as a CDRS-R score of &lt;28. (The total score is the sum of the ratings on each of the 17 items.)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Low Dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Fish Oil</intervention_name>
    <description>Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)</description>
    <arm_group_label>Low Dose Fish Oil</arm_group_label>
    <other_name>OmegaRx - Zone Laboratories</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Fish Oil</intervention_name>
    <description>Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)</description>
    <arm_group_label>High Dose Fish Oil</arm_group_label>
    <other_name>OmegaRx - Zone Laboratories</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:

          -  Between the ages of 12-18 years.

          -  Diagnosis of MDD and not exhibited symptom remission CDRS-R (&gt; 28 but &lt; 40) despite
             being administered a standard therapeutic dose of an SSRI continuously for a minimum
             of 6 weeks.

          -  Ability and willingness to provide assent and informed, written consent from at least
             one biological parent.

          -  Present with biological parent or legal guardian.

          -  Willingness to maintain current dietary habits.

          -  Permission from treating physician

          -  Able to perform fMRI/MRS.

        Exclusion Criterion:

          -  Inability or unwillingness to provide consent.

          -  Antecedent or concurrent serious medical illness.

          -  Clinically unstable medical disease, including cardiovascular, hepatic insufficiency,
             severe renal impairment, gastrointestinal, pulmonary, metabolic, endocrine, obesity or
             other systemic disease.

          -  History of seizures, excluding febrile seizures in childhood.

          -  Patients requiring treatment with any drug which might obscure the action of the study
             treatment.

          -  Female patients who are either pregnant or lactating.

          -  Clinically significant laboratory abnormalities in the last year on CBC or TSH tests.

          -  Judged clinically to be at suicidal risk (defined as having active suicidal ideation,
             intent or plan, or a serious suicide attempt within the past 6 months, or a baseline
             CDRS-R suicide score of &gt;3).

          -  Hospitalized within the last 3 months

          -  Greater than 1 year outside appropriate age/grade level

          -  Pacemaker

          -  Cerebral aneurysm clip

          -  Cochlear implant

          -  Metal fragments lodged within the eye or braces

          -  Claustrophobia

          -  Necessity of sedation (no sedation will be given).

          -  History of loss of consciousness &gt; 10 minutes in duration

          -  Allergy to seafood.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert McNamara, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>March 21, 2013</results_first_submitted>
  <results_first_submitted_qc>December 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2014</results_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert McNamara</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Sadness</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Loss of appetite</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Trouble thinking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in August, 2007 at the University of Cincinnati, Medical Sciences Building.</recruitment_details>
      <pre_assignment_details>A total of 24 patients were screened and 20 patients met inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Fish Oil</title>
          <description>Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
High Dose Fish Oil : Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Fish Oil</title>
          <description>Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
Low Dose Fish Oil : Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7">2 terminated for worsening symptoms;1 refused a scan;2 lost to follow up (could not be contacted)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused second scn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Fish Oil</title>
          <description>Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
High Dose Fish Oil : Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Fish Oil</title>
          <description>Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
Low Dose Fish Oil : Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="3.2"/>
                    <measurement group_id="B2" value="16.7" spread="2.9"/>
                    <measurement group_id="B3" value="15.0" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression Score</title>
          <description>Patients were required to have a baseline score of &gt;28 and &lt;40 on the Children Depression Rating Scale-Revised (CDRS-R) despite being administered a standard therapeutic dose of an SSRI for a minimum of 6 weeks.</description>
          <units>CDRS-R Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="3.1"/>
                    <measurement group_id="B2" value="31.9" spread="6.5"/>
                    <measurement group_id="B3" value="32.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mood Symptoms Ratings</title>
        <description>Depression symptom severity was determined with the Children’s Depression Rating Scale-Revised (CDRS-R), which is a brief rating scale based on a semi-structured interview with the child. It is a 17-item observer-rated questionnaire where the 17 symptom areas are rated on a 6- or 7-point scale. Total score ranges from a low (not depressed) of 17 to a maximum (very depressed) of 108. Remission was defined as a CDRS-R score of &lt;28. (The total score is the sum of the ratings on each of the 17 items.)</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline CDRS-R: High Dose Fish Oil</title>
            <description>CDRS-R scores were computed for High Fish Oil groups.</description>
          </group>
          <group group_id="O2">
            <title>Baseline CDRS-R: Low Dose Fish Oil</title>
            <description>CDRS-R scores were computed for Low Fish Oil groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Mood Symptoms Ratings</title>
          <description>Depression symptom severity was determined with the Children’s Depression Rating Scale-Revised (CDRS-R), which is a brief rating scale based on a semi-structured interview with the child. It is a 17-item observer-rated questionnaire where the 17 symptom areas are rated on a 6- or 7-point scale. Total score ranges from a low (not depressed) of 17 to a maximum (very depressed) of 108. Remission was defined as a CDRS-R score of &lt;28. (The total score is the sum of the ratings on each of the 17 items.)</description>
          <units>CDRS-R score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="1.5"/>
                    <measurement group_id="O2" value="33.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Fish Oil</title>
          <description>Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
High Dose Fish Oil : Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Fish Oil</title>
          <description>Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
Low Dose Fish Oil : Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of depressive symptoms</sub_title>
                <description>Two patients in teh Low Dose Groupt experienced worsening of depressive symptoms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert McNamara, PhD</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-5601</phone>
      <email>robert.mcnamara@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

